U.S. Patent Issued for Novel Antimicrobial Identification Method

We are excited to announce that Chris Cox and Andy Logan have been issued a United States patent for our innovative technology, "Method and Kit for Identifying Antimicrobial Agents and Effective Concentrations Thereof." The patent was officially granted on April 14, 2026, and represents a significant milestone in our work to advance the fight against infectious disease and antimicrobial resistance. 

The newly patented method and accompanying kit provide a powerful approach to identifying which antimicrobial agents are effective against a given pathogen, and at what concentrations they work best. In an era when antimicrobial resistance is one of the most urgent global health challenges, tools that enable faster, more precise identification of effective treatments have the potential to meaningfully improve patient outcomes and inform smarter clinical and research decisions. 

Securing this patent is the culmination of years of dedicated research, rigorous experimentation, and a deep commitment to scientific excellence by our team. It also reinforces the strength of our intellectual property portfolio and positions Cobio to continue building on this foundation as we expand our platform and pursue commercialization. 

We are grateful to our scientific team, advisors, collaborators, and partners whose contributions made this achievement possible. This patent is more than a legal milestone — it is a validation of our science and a stepping stone toward delivering meaningful impact in the fight against infectious disease.